A Phase II Neo-adjuvant Study Assessing TCH (Docetaxel, Carboplatin and Trastuzumab) and TCHL (Docetaxel, Carboplatin, Trastuzumab and Lapatinib) in HER-2 Positive Breast Cancer Patients
Phase of Trial: Phase II
Latest Information Update: 14 Aug 2018
At a glance
- Drugs Lapatinib (Primary) ; Trastuzumab (Primary) ; Carboplatin; Docetaxel
- Indications Advanced breast cancer
- Focus Therapeutic Use
- Acronyms TCHL-Phase-II
- 05 Aug 2018 Status changed from active, no longer recruiting to completed.
- 10 Jun 2017 Biomarkers information updated
- 02 Jun 2017 Results (n=78) presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.